correlates with protective outcome or disease exacerbation, depending on the context. In human cancers, TLS can be found in primary tumors [2] and in metastatic sites [1] . In all human cancer types tested so far, TLS density correlated with patient's favorable clinical outcome, and recent developments also suggest that TLS formation is associated with cancer patients' response to immunotherapy (reviewed in [1] ). These observations, together with the coordinated CD8 + memory T cell and Th1 gene signature detected in the immune infiltrates of lung tumors with high TLS densities, have led to the concept that TLS allow the initiation and/or maintenance of a local and systemic adaptive immune response that protects patients against tumor invasion and metastasis [3] . However, animal models that could enable a comprehensive understanding of the function of TLS in cancer were lacking, with the exception of the signs of lymph node like-vasculature detected in B16 melanoma tumors [4] .
Two recent articles using genetically engineered mouse models (GEMM) of lung cancer [5] and hepatocellular carcinoma (HCC) [6] shed light on TLS regulation and function and provide new insight on their role in cancer development.
Joshi et al. [5] Finkin et al. [6] developed an inflammation-driven HCC model by expressing constitutively the active form of IKK-B in hepatocytes to activate the NF-B pathway, a situation that occurs in common forms of chronic hepatitis in humans [6, 8] . . One major issue now is to find whether ELS niches for tumor progenitor cells can be found in other inflammed organs than the liver and be associated to cancer recurrence in other cancers than HCC, a concept which would need to re-visit the current litterature. These findings add complexity to our understanding of TLS that prompts further study of these dynamic structures. Hepatitis-associated ELS may serve as a "field" for carcinogenesis and provide a niche to produce de novo malignant tumors independently from the removed primary tumor (white). 
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